Welcome to our dedicated page for Biodexa Pharmaceuticals news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals stock.
Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced positive Phase 2 clinical trial results of its new drug eRapa for treating Familial Adenomatous Polyposis (FAP). The trial, involving 30 adult patients at seven U.S. centers, showed an 83% non-progression rate at six months and a statistically significant 24% reduction in overall mean polyp burden (p=0.04). The study was partially funded by a $20M grant from the Cancer Prevention and Research Institute of Texas. The results will be presented at the 2024 Digestive Disease Week annual meeting. The drug appeared safe and well-tolerated, with 97% of patients remaining on treatment at six months.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has posted its Annual Report for the year ending December 31, 2023, and issued a Notice of Annual General Meeting (AGM) to shareholders. The AGM will be held on June 13, 2024, at the company's offices in Cardiff. Shareholders are provided with information on how to vote by proxy. The company's issued share capital consists of 2,238,225,722 Ordinary Shares with voting rights. Biodexa does not hold shares in treasury, and each American Depositary Share comprises 400 Ordinary Shares.
Biodexa Pharmaceuticals (NASDAQ:BDRX) is set to start phase 3 clinical trials for eRapa to combat Familial Adenomatous Polyposis (FAP), a precancerous condition leading to colorectal cancer. The acquisition of eRapa, supported by a $17 million grant, marks Biodexa's second portfolio expansion in six months, strengthening its position in the biopharmaceutical industry. The potentially life-changing eRapa could be the first drug to treat FAP, offering hope to patients facing invasive surgeries and lifelong complications.
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washington DC. Biodexa recently acquired exclusive rights to eRapa, showcasing its commitment to developing innovative treatments for unmet medical needs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.